PTCT Q2 2018 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$69M+43.3% YoY

Gross Profit

$66M96.3% margin

Operating Income

-$6M-8.1% margin

Net Income

-$10M-13.8% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+22.6%

Cash Flow

Operating Cash Flow

$3,000

Free Cash Flow

-$705,000

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$512M

Total Liabilities

$244M

Stockholders' Equity

$267M

Cash & Equivalents

$224M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$48M	+43.3%
Gross Profit	$66M	$47M	+40.2%
Operating Income	-$6M	-$12M	+55.4%
Net Income	-$10M	-$17M	+45.5%

Revenue Segments

Licensing And Collaboration Agreement

$100,000100%